Ibrance (palbociclib) is a targeted cancer medication used to treat advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative. It works by blocking specific proteins that drive cancer cell growth, and it is always prescribed alongside hormone therapy rather than on its own.
The Specific Type of Breast Cancer Ibrance Treats
Ibrance is FDA-approved for adults with breast cancer that meets two biological criteria. First, the cancer must be hormone receptor-positive (HR+), meaning the tumor grows in response to estrogen or progesterone. Second, the cancer must be HER2-negative, meaning it does not overproduce the HER2 protein. This combination, HR+/HER2-, is the most common subtype of breast cancer, accounting for roughly 70% of all cases.
The drug is specifically approved for advanced or metastatic disease. “Advanced” generally means the cancer has grown locally beyond what surgery can remove, while “metastatic” means it has spread to other parts of the body such as the bones, liver, or lungs. Ibrance is not currently approved for early-stage breast cancer that hasn’t spread.
How Ibrance Works
Cancer cells rely on a cycle of growth and division to spread. Two proteins called CDK4 and CDK6 act like switches that push cells through this cycle. Ibrance is a CDK4/6 inhibitor, which means it blocks those switches and stalls the cancer cell’s ability to divide. By pairing this action with hormone therapy that cuts off the estrogen fueling the tumor, the two treatments attack the cancer from different angles simultaneously.
Combination Treatments Used With Ibrance
Ibrance is never taken alone. The FDA has approved it in several combination regimens depending on where a patient is in their treatment journey.
- As a first-line treatment: Ibrance is paired with an aromatase inhibitor, a class of hormone therapy that lowers estrogen levels. This combination is typically the starting point for patients who haven’t yet received treatment for advanced disease.
- After prior hormone therapy: For patients whose cancer has progressed on a previous hormone treatment, Ibrance is combined with fulvestrant, an injectable drug that blocks and degrades estrogen receptors on cancer cells.
- For PIK3CA-mutated cancers: A newer approval allows Ibrance to be used alongside both inavolisib and fulvestrant for patients with a specific gene mutation (PIK3CA) whose cancer has returned after or during adjuvant hormone therapy.
Premenopausal and perimenopausal women receiving any of these combinations also need ovarian suppression therapy, because their ovaries still produce significant estrogen. Men with HR+/HER2- breast cancer may also be treated with Ibrance in these same combinations.
How Effective Ibrance Is
The major clinical trials behind Ibrance’s approval showed it roughly doubles the time before the cancer worsens. In the PALOMA-3 trial, which studied patients whose cancer had progressed on prior hormone therapy, adding Ibrance to fulvestrant extended median progression-free survival from 4.6 months to 11.2 months compared to fulvestrant alone. That difference was statistically significant, meaning it was very unlikely to be due to chance.
These benefits held across patient groups. An analysis by menopausal status showed that both premenopausal/perimenopausal and postmenopausal women experienced improved progression-free survival when Ibrance was added to their treatment. Progression-free survival measures how long a patient lives without the cancer growing or spreading further. It doesn’t capture the full picture of long-term outcomes, but it is a meaningful indicator of how well the drug controls the disease.
What the Treatment Schedule Looks Like
Ibrance is an oral medication taken as a capsule once a day with food. The standard dose is 125 mg. Treatment follows a repeating 28-day cycle: you take the capsule every day for 21 days, then take 7 days off before starting the next cycle. This on-off rhythm gives the body time to recover, particularly the bone marrow, which is sensitive to the drug’s effects.
Some patients take a lower dose. People with severe liver impairment start at 75 mg, and the dose may also be reduced to 75 mg for anyone taking certain medications that interact with how the body processes Ibrance. Dose reductions can also happen during treatment if side effects become too intense, and your oncologist will adjust the schedule based on blood work results.
Side Effects to Expect
The most notable side effect of Ibrance is a drop in white blood cell counts, particularly a type called neutrophils that help fight infection. This condition, called neutropenia, occurs in the majority of patients and is the most common reason for dose adjustments. Most of the time it’s manageable and doesn’t cause symptoms on its own, but it does increase vulnerability to infections.
Other common side effects include fatigue, nausea, mouth sores, hair thinning, and diarrhea. Many patients also experience joint pain and reduced appetite. These effects vary widely in severity from person to person, and some people tolerate the drug well enough to stay on it for months or even years.
Blood Work and Monitoring
Because of the impact on white blood cells, regular blood tests are a non-negotiable part of treatment with Ibrance. A complete blood count is required before starting therapy and at the beginning of each cycle. During the first two cycles, an additional blood draw happens on Day 15 to catch any sharp drops early.
If your counts stay relatively stable through the first six cycles (no worse than a mild decrease), monitoring eases to every three months before the start of a new cycle. Your oncologist may still order extra tests if you develop signs of infection like a fever. These blood tests are what guide decisions about whether to continue at the current dose, reduce it, or temporarily pause treatment.